Citi Appointed as Depositary Bank for Exscientia plc’s ADR Programme

Rhea-AI Summary

Citi has been appointed as the depositary bank for Exscientia's ADR program, facilitating American Depositary Shares trading on Nasdaq under symbol EXAI. Each ADS represents one ordinary share, enhancing Exscientia's investor outreach. With a commitment to AI-driven drug development, Exscientia has made significant strides, including the advancement of over 25 projects and the launch of three AI-designed drug candidates into Phase 1 clinical trials. This partnership aims to leverage Citi's expertise in investor relations and global equity distribution.

Positive

• Appointment of Citi as depositary bank for Exscientia's ADR program enhances investor outreach.
• Exscientia is advancing over 25 projects, including three AI-designed drug candidates in Phase 1 trials.

Negative

• None.

LONDON--(BUSINESS WIRE)-- Citi, acting through Citibank N.A., has been appointed by Exscientia plc (“Exscientia”), an AI-driven pharmatech company committed to designing and developing the best possible drugs in the fastest and most effective manner, to act as depositary bank for its American Depositary Receipt (“ADR”) programme.

Exscientia’s American Depositary Shares (“ADS”) trade on the Nasdaq Global Market under the symbol “EXAI”. Each ADS represents one ordinary share of the company.

Commenting on the appointment, Dirk Jones, Global Head of Issuer Services, at Citi said: “We look forward to supporting Exscientia’s ADR programme and expanding the company’s investor outreach through the expertise of our Investor Relations Advisory team and the breadth of our global equity distribution network.”

For more information on Citi’s Depositary Receipt Services, please visit www.citi.com/dr

About Exscientia

Exscientia is an AI-driven pharmatech company committed to discovering, designing and developing the best possible drugs in the fastest and most effective manner. Exscientia developed the first-ever functional precision oncology platform to successfully guide treatment selection and improve patient outcomes in a prospective interventional clinical study, as well as to progress AI-designed small molecules into the clinical setting. Our pipeline demonstrates our ability to rapidly translate scientific concepts into precision-designed therapeutic candidates, with more than 25 projects advancing, including the first three AI-designed drug candidates to enter Phase 1 clinical trials. Exscientia has offices in Oxford, Miami, Vienna, Osaka and Dundee.

About Citi

Citi, the leading global bank, has approximately 200 million customer accounts and does business in more than 160 countries and jurisdictions. Citi provides consumers, corporations, governments and institutions with a broad range of financial products and services, including consumer banking and credit, corporate and investment banking, securities brokerage, transaction services, and wealth management.

Additional information may be found at www.citigroup.com | Twitter: @Citi | YouTube: www.youtube.com/citi | Blog: http://blog.citigroup.com | Facebook: www.facebook.com/citi | LinkedIn: www.linkedin.com/company/citi

View source version on businesswire.com: https://www.businesswire.com/news/home/20211006005061/en/

Citi Media Contacts:

Shani Halstead

+44 (0) 20 7508 2352

shani.halstead@citi.com



Exscientia Enquiries:

Investors:

Sara Sherman

investors@exscientia.ai



Media:

Amanda Galgay

media@exscientia.ai

Source: Citi

FAQ

What is the significance of Citi's appointment for Exscientia's stock symbol EXAI?

Citi's appointment as the depositary bank for Exscientia's ADR program enhances the company's investor outreach, potentially increasing interest in its stock symbol EXAI.

How many drug projects is Exscientia advancing as of the latest press release?

Exscientia is advancing over 25 drug projects, including three AI-designed drug candidates that have entered Phase 1 clinical trials.

What do American Depositary Shares represent for Exscientia?

Each American Depositary Share (ADS) for Exscientia represents one ordinary share of the company, traded under the symbol EXAI on Nasdaq.

How does Citi plan to support Exscientia's ADR program?

Citi aims to support Exscientia's ADR program by leveraging its Investor Relations Advisory team and extensive global equity distribution network.